Search
for
Sort by
Research 331–360 of 525
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- New therapies for alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Treatment of frontal fibrosing alopecia: literature review 2020-2025
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Oral tofacitinib for recalcitrant lichen planus pigmentosus: A hospital-based retrospective study
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- The Frontal Fibrosing Alopecia Treatment Dilemma
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3